These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 3478543

  • 21. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
    Yamauchi T, Kawai Y, Kishi S, Goto N, Urasaki Y, Imamura S, Fukushima T, Yoshida A, Iwasaki H, Tsutani H, Masada M, Ueda T.
    Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
    [Abstract] [Full Text] [Related]

  • 22. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
    Danhauser L, Plunkett W, Keating M, Cabanillas F.
    Cancer Chemother Pharmacol; 1986 May; 18(2):145-52. PubMed ID: 2431803
    [Abstract] [Full Text] [Related]

  • 23. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE, Plunkett W, Linker CA.
    Cancer Res; 1991 Aug 15; 51(16):4141-5. PubMed ID: 1868435
    [Abstract] [Full Text] [Related]

  • 24. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J, Hohenlöchter B, Schulze-Westhoff P, Schiller M, Zimmermann M, Creutzig U, Ritter J, Jurgens H.
    Med Pediatr Oncol; 1996 Jun 15; 26(6):397-404. PubMed ID: 8614376
    [Abstract] [Full Text] [Related]

  • 25. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar 15; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 26. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW, Cheng YC, Schabel FM, Montgomery JA.
    Cancer Res; 1980 Oct 15; 40(10):3610-5. PubMed ID: 6254636
    [Abstract] [Full Text] [Related]

  • 27. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V, Xu YZ, Estey E.
    Clin Cancer Res; 1998 Jul 15; 4(7):1719-26. PubMed ID: 9676847
    [Abstract] [Full Text] [Related]

  • 28. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov 15; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
    Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W.
    Cancer Chemother Pharmacol; 1992 Nov 15; 31(3):193-9. PubMed ID: 1464155
    [Abstract] [Full Text] [Related]

  • 30. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP, Preisler HD, Slocum H, Rustum YM.
    Cancer Res; 1982 Apr 15; 42(4):1587-94. PubMed ID: 6949642
    [Abstract] [Full Text] [Related]

  • 31. Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice.
    Avramis VI.
    Cancer Invest; 1989 Apr 15; 7(2):129-37. PubMed ID: 2477118
    [Abstract] [Full Text] [Related]

  • 32. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
    Koehl U, Hollatz G, Rohrbach E, Visschedyk K, Cinatl J, Kornhuber B, Kreuter J, Mutschler E, Schwabe D.
    Cancer Chemother Pharmacol; 2007 Sep 15; 60(4):467-77. PubMed ID: 17171362
    [Abstract] [Full Text] [Related]

  • 33. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S, Yamauchi T, Kawai Y, Takemura H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Int J Hematol; 2007 Feb 15; 85(2):108-15. PubMed ID: 17321987
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S.
    Leukemia; 1991 Nov 15; 5(11):991-8. PubMed ID: 1961042
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Malspeis L, Grever MR, Staubus AE, Young D.
    Semin Oncol; 1990 Oct 15; 17(5 Suppl 8):18-32. PubMed ID: 1699279
    [Abstract] [Full Text] [Related]

  • 40. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V, Estey E, Keating MJ, Plunkett W.
    Leuk Lymphoma; 1993 Oct 15; 10 Suppl():109-14. PubMed ID: 8481660
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.